Cencora, Inc. (COR)
NYSE · Healthcare · Medical Distribution
$314.93+1.90%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $60.1B
- P/E (trailing)
- 22.9
- Forward P/E
- 15.9
- Dividend yield
- 0.8%
- 52-week range
- $244.82 – $377.54
- 52-week change
- +0.11%
- EPS (trailing)
- $13.73
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Sep 2025
- Revenue
- $321B (+9.31%)
- Net income
- $1.6B
- Operating margin
- 0.8%
- Diluted EPS
- $7.96
- Free cash flow
- $3.2B
From the company’s annual report on SEC EDGAR.
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers;…
Headquarters: Conshohocken, United States · 47,000 employees · cencora.com